240
Participants
Start Date
August 30, 2024
Primary Completion Date
October 31, 2025
Study Completion Date
October 31, 2025
R21
R21 is a portion of Pf circumsporozoite protein fused with hepatitis B surface antigen in the form of non-infectious virus-like particles (VLPs) produced in yeast cells (Hansenula) by recombinant DNA technology.
Pfs230D1-CRM197
Recombinant Pfs230 domain 1 (Pfs230D1; a subdomain of a surface antigen of gametocytes, gametes, and zygotes, in the mosquito stage of Pf conjugated to CRM197 and adjuvanted with 50μg of Matrix-M.
Pfs230D1-EPA
Recombinant Pfs230D1 conjugated to a recombinant Pseudomonas aeruginosa ExoProtein A (EPA)
Matrix-M
Vaccine adjuvant that contains purified saponin (from Quillaja saponaria Molina) and cholesterol and phosphatidyl choline. Matrix-M will be used at a 50μg dose for vaccinations.
University of Science, Technique and Technology of Bamako (Usttb), Bamako
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Serum Institute of India Pvt. Ltd.
INDUSTRY